Background-Low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol are established risk factors for vascular disease, but lipoprotein particle concentrations may be stronger determinants of risk.
of prospective observational studies of individuals without prior vascular disease, the lower CHD risk associated with 1-SD-higher HDL-C attenuated from 29% to 22% after adjustment for non-HDL-C and was only about half the size of the 56% higher risk associated with 1-SD-higher non-HDL-C. 2 The extent to which LDL and HDL particles influence risk through atherosclerosis, inflammation, and other postulated mechanisms may vary according to subtypes of lipoprotein particle. [7] [8] [9] Small dense LDL particles are believed to be particularly hazardous, but it is unclear whether these associations are independent of other lipid measures. 8,10 -12 Studies comparing different HDL subtypes (based on size, density, or apolipoprotein content) 13 have yielded conflicting results about the relevance of different subtypes. 14 Discordance in results may be attributable to small study sizes and variable allowance for associations with the LDL system. Preexisting disease in participants may also be a confounding factor because cardiac disease can reduce the functionality of HDL particles. 15 LDL and HDL are traditionally quantified by measuring the cholesterol they contain (LDL-C and HDL-C), but interindividual variations in the cholesterol content of LDL and HDL particles could mean that alternative analytic measures are more informative. 16 -18 One approach is to measure the predominant protein moiety on the particles: apoB for LDL and apolipoprotein A 1 (apoA 1 ) for HDL. LDL particles and their precursors each carry 1 molecule of apoB on their surface (with Ϸ90% of apoB being on LDL particles); thus, plasma apoB concentrations provide a good estimate of LDL particle concentrations. Plasma apoA 1 concentrations, in contrast, are not proportional to HDL particle concentrations because HDL particles contain variable numbers (2-5) of apoA 1 molecules. Nuclear magnetic resonance (NMR) spectroscopy offers another way to quantify lipoproteins, providing particle concentrations of LDL (LDL-P) and HDL (HDL-P) and their subclasses. 19 The present analyses investigate the associations of cholesterol, apolipoprotein, and particle measures of LDL and HDL, as well as subclass levels, with Ͼ5000 vascular outcomes in 20 000 high-risk individuals during 5 years of follow-up in the MRC/BHF Heart Protection Study (HPS).
Methods

Recruitment and Eligibility Criteria
Details of the HPS have been reported previously. 20, 21 Between 1994 and 1997 in the United Kingdom, 20 536 men and women 40 to 80 years of age were recruited and assigned randomly to receive 40 mg simvastatin daily or matching placebo (and separately, in a 2ϫ2 factorial design, to receive antioxidant vitamins or placebo capsules). To be eligible, participants had a nonfasting blood total cholesterol concentration of at least 3.5 mmol/L (135 mg/dL) and either had a previous diagnosis of CHD, cerebrovascular disease, other occlusive disease of noncoronary arteries, or diabetes mellitus (type I or II) or were men Ն65 years of age undergoing treatment for hypertension. Individuals were excluded if their doctor considered statin therapy clearly indicated or contraindicated. At initial screening, written consent to participate was obtained, and a nonfasting blood sample was taken (screening sample); participants then began a run-in phase involving 4 weeks of placebo followed by 4 to 6 weeks of 40 mg simvastatin daily plus vitamin supplementation. At the end of this run-in period, a nonfasting blood sample was taken (randomization sample), and compliant and eligible individuals were randomly assigned treatment for Ϸ5 years.
Laboratory Measurements
Blood samples taken into heparinized vacutainers at screening and randomization visits were chilled to Ϸ4°C and couriered overnight to the coordinating central laboratory for separation, assay, and long-term storage in liquid nitrogen (ϽϪ80°C). Analyses for this report were based on the screening samples for participants subsequently randomly allocated to placebo-simvastatin at the randomization visit and on the randomization samples (after taking the simvastatin regimen) for participants who were subsequently randomly allocated to active simvastatin. Plasma lipid fractions (including HDL-C, apoB, and apoA 1 ), triglycerides, creatinine, N-terminal pro-B-type natriuretic peptide (N-BNP), and C-reactive protein were assayed with previously reported methods. 4, 21, 22 Because methods for LDL-C have progressed, LDL-C was reassayed with the N-geneous method (Genzyme Diagnostics). 23 Lipoprotein particle profiles were measured by NMR spectroscopy with the LipoProfile-3 algorithm at LipoScience, Inc (Raleigh, NC). LDL and HDL particle subclasses (mol/L) were quantified from the amplitudes of their spectroscopically distinct lipid methyl group NMR signals, and weighted-average LDL and HDL sizes were derived from the sum of the diameter of each subclass multiplied by its relative mass percentage based on the amplitude of its methyl NMR signal. 19 Diameter range estimates for the subclasses were as follows: small LDL-P, 18 to 21.2 nm; large LDL-P, 21.2 to 23 nm; intermediatedensity lipoprotein particles, 23 to 27 nm; small HDL-P, 7.3 to 8.2 nm; medium HDL-P, 8.2 to 8.8 nm; and large HDL-P, 8.8 to 13 nm. LDL-P and HDL-P are the totals of the particle number concentrations of the LDL and HDL subclasses, respectively. The glomerular filtration rate was estimated with the Modification of Diet in Renal Disease formula. 24 During the study, blood was collected annually from a random sample of participants attending follow-up. Repeat NMR and chemistry measurements in the 4000 participants with available samples taken while compliant with their allocated statin treatment allowed assessment of the reproducibility of each lipid measure.
Follow-Up and Determination of Events
Participants were followed up for the incidence of events, including MI, stroke, vascular procedures, death, and hospital admissions for other cardiac events (ascertained as previously reported in detail) 20 ; this report includes a mean of 5.3 years of follow-up until November 11, 2001 , when study treatment ended. Because most deaths from heart failure and sudden death were believed to have an underlying coronary cause, they had been included in the prespecified trial outcome of major coronary event (nonfatal MI or coronary death). However, because some such deaths may have had nonocclusive causes (eg, arrhythmia), the following outcome categories were used in the present analyses: major occlusive coronary event, defined as nonfatal MI or coronary death other than death from heart failure or sudden death (corresponding to the revised definition of major coronary event in the recent Cholesterol Treatment Trialists' metaanalyses 3 ), and other cardiac events, defined as hospitalization or death resulting from heart failure, sudden death, or noncoronary cardiac death.
Compliance
Among those allocated placebo, noncompliance resulting from the uptake of statin therapy increased during the course of the study and was greater among those with higher baseline cholesterol levels (3% versus 29% at 3 years in the bottom versus top quintile of baseline non-HDL-C). This bias would tend to attenuate the observed associations of risk with LDL-related measures but not affect the associations with HDL-related measures. Because a determinant of such statin use may have been a high LDL-C or non-HDL-C level, use may be more directly related to cholesterol levels than to the levels of other LDL-related measures (such as LDL-P or apoB) and so lead to greater attenuation of associations with LDL-C and non-HDL-C than of associations with LDL-P and apoB (see the online-only Data Supplement). When considering comparisons between LDL-related measures, we have therefore placed particular emphasis on the results in the statin arm to reduce the potential for such confounding.
Statistical Analysis
Hazard ratios (HRs) were calculated for the first postrandomization occurrence of each outcome per 1-SD-higher level of the baseline lipid-related factor with Cox proportional hazards regression. Standard adjustment in risk analyses included simvastatin and vitamin allocation, baseline 5-year age group by sex, prior history of vascular disease or diabetes mellitus (as a 3-way variable for CHD [MI, other CHD, no CHD] and a 5-way variable for cerebrovascular disease, peripheral vascular disease, and diabetes mellitus [each alone, multiple, none]), treated hypertension, medication use (angiotensinconverting enzyme inhibitors, anticoagulants, ␤-blockers, bronchodilators, calcium antagonists, digoxin, diuretics, hormone replacement therapy, hypoglycemics, inhaled steroids, insulin), cigarette smoking status (current, ex-smoker, never), systolic blood pressure, and estimated glomerular filtration rate as continuous variables, and N-BNP as a categorical variable with 5 groups (cut points: 400, 1000, 2000, and 5000 pg/mL based around the ESC guidelines that grade N-BNP Ͻ400 pg/mL as heart failure unlikely and N-BNP Ͼ2000 pg/mL as heart failure likely 25 ). The median value was substituted for the few missing values for any covariate (Ͻ0.7%). The SD of a lipid-related factor was estimated by the root mean square error in a regression of the factor on the standard adjustment terms. For LDL subclasses, the SD of the total particle concentration was used so that all the HRs were per the same unit of particle number, facilitating comparison of whether the hazard per particle varied by subclass; likewise, hazard ratios for HDL subclasses were calculated per SD of HDL-P. Likelihood ratio tests, yielding 2 statistics and corresponding P values, were used to assess evidence of association after progressive inclusion of terms. Pearson correlation coefficients were used except in correlations involving N-BNP when Spearman were used. All analyses were based on the 20 021 participants with complete information on concentrations of NMR particles, cholesterol fractions, and apolipoproteins.
Results
During a mean follow-up of 5.3 years, 1796 participants had a major occlusive coronary event, 2187 had a revascularization, 1043 had an "other" cardiac event, and 995 had a presumed ischemic stroke ( Table 1) . History of occlusive vascular disease and indicators of heart failure 25, 26 were major determinants of the incidence of vascular events ( Table I in the online-only Data Supplement), highlighting the importance of adjusting for these factors in all analyses. The mean concentrations of the directly measured chemistries and the NMR lipoprotein subclasses are shown in Table II in the online-only Data Supplement, together with self-correlations that indicate the reproducibility of measurements in samples collected from the same individual a few years apart. All of the LDL-related factors except intermediate-density lipoprotein particle number showed similar self-correlations of Ϸ0.65 on statin and 0.75 off statin. The self-correlations of the different HDL-related factors showed greater variation but were similar on and off statin (eg, off-statin selfcorrelations: 0.83, 0.67, 0.73, and 0.60 for HDL-C, apoA 1 , HDL-P, and small HDL-P, respectively).
Correlations Between LDL-and HDL-Related Measures
The 4 total LDL-related measures were strongly correlated with each other in measurements made in the same samples (Table 2) : non-HDL-C and apoB were the most strongly correlated (0.93), whereas LDL-P was correlated most strongly with apoB (0.84) and least strongly with LDL-C (0.79). The 3 total HDL-related measures were less strongly correlated with each other (pairwise correlation coefficients between 0.61 and 0.81; Table 2 ). The LDL-and HDL-related measures were considerably intercorrelated. LDL size and HDL size were positively correlated with each other (0.53); both were negatively correlated with LDL-P and triglycerides and positively correlated with HDL-P. HDL-C was more strongly negatively correlated with several LDL-related measures than was HDL-P (eg, correlations of Ϫ0.34 and Ϫ0.10, respectively, with LDL-P and of Ϫ0.46 and 0.06 with log triglycerides). Figure 1 compares the hazard ratios and 2 statistics for the strengths of associations of LDL-C, non-HDL-C, apoB, and LDL-P for several different outcomes after adjustment for 1 †Major coronary event (as defined in the protocol of the Heart Protection Study clinical trial) is composed of these events.
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Lipids, Lipoproteins, and Vascular Events baseline covariates. Major occlusive coronary event and revascularization showed clear associations with all 4 LDLrelated measures in both the statin and placebo arms, whereas other cardiac event and ischemic stroke showed only weak associations with these measures. In the statin arm, the LDL particle measures (apoB and LDL-P) and the cholesterol measures (LDL-C and non-HDL-C) showed similar strengths of association with major occlusive coronary event: HR of 1.23 (95% confidence interval [CI], 1.15-1.33) and 1.25 (95% CI, 1.16 -1.35) for apoB and LDL-P, respectively, and 1.25 (95% CI, 1.16 -1.34) and 1.22 (95% CI, 1.14 -1.32) for LDL-C and non-HDL-C, respectively ( Figure 1 ). Findings were similar for revascularization ( Figure 1 ) and for the combined outcome of major occlusive coronary event or revascularization (HRs between 1.19 and 1.20; Figure I in the online-only Data Supplement). In the placebo arm, the associations of all of the measures with the combined outcome were weaker than in the statin arm, but (given that some bias might arise from compliance associations) there was no clear evidence of any differences between the measures. The separate HRs for major occlusive coronary event and revascularization (Figure 1 ) were statistically compatible with the results for the combined outcome ( Figure I in the online-only Data Supplement). Including lower density particles with LDL-P made little difference, but total cholesterol was a weaker predictor than LDL-C or non-HDL-C ( Figure  I in the online-only Data Supplement). Table 3 shows the associations of LDL subclasses with major occlusive coronary event in the statin arm. Considered singly, the association with small LDL-P was stronger than that with large LDL-P, but both were weaker than the association with LDL-P. The 2 3 for the strength of the association with the 3 LDL subclasses jointly was the same as that for LDL-P alone (32.4 versus 32.3), indicating that the LDL subclasses did not contribute any additional predictive value over LDL-P. A similar pattern was seen for revascularization. The strengths of the associations with the main LDL-P subclasses individually corresponded to their respective correlations with LDL-P (correlation coefficient: 0.76 for small LDL-P, 0.16 for large LDL-P; Table 2 ). Figure 2 contrasts the associations of different HDL-related measures, given LDL-P, with various vascular outcomes in all participants. (Associations in the statin and placebo arms separately were similar and are given in Figure II in the online-only Data Supplement.) For major occlusive coronary event, the HRs were Ϸ0.90, with HDL-P showing a slightly stronger association than HDL-C and apoA 1 ( 2 1 : 22.5, 13.2, and 13.1, respectively), whereas for revascularization, only 
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LDL-C indicates low-density lipoprotein cholesterol
; HDL-C, high-density lipoprotein cholesterol; apo, apolipoprotein; LDL-P, particle concentration of LDL; IDL-P, particle concentrations of intermediate-density lipoprotein; HDL-P, particle concentration of HDL; N-BNP, N-terminal pro-B-type natriuretic peptide; CRP, C-reactive protein; BMI, body mass index; and eGFR, estimated glomerular filtration rate.
*Adjusted for age, sex, simvastatin and vitamin allocation, prior disease, systolic blood pressure, smoking, eGFR, log N-BNP, and medication. †Available in screening samples only (nϭ9988). ‡Not adjusted for eGFR. §Available for 19 857 participants.
HDL-C showed much association ( 2 1 , 15.9). For both outcomes, however, the CIs for all 3 measures overlapped. Table 4 shows the associations of the HDL subclasses with major occlusive coronary event in all participants both with and without adjustment for LDL-P. Without such adjustment, HDL-C and HDL-P showed similar strengths of association with major occlusive coronary event risk. However, these associations derived partly from negative correlations with LDL-related measures (correlations of large HDL-P and HDL-C with LDL-P, Ϫ0.44 and Ϫ0.34, respectively; Table  2 ). Hence, given LDL-P, the strengths of association with major occlusive coronary event were reduced, becoming †All standard deviations are as in Figure 1 . ‡HRs for all LDL subclasses are per 0.34 mol/L (1 SD of LDL-P). §Calculated from the difference between the 2 3 for the subclasses jointly and the 2 1 for LDL-P alone.
slightly weaker for HDL-C than for HDL-P. The 2 3 for the strength of association with the 3 HDL subclasses jointly was minimally greater than that for HDL-P alone (24.0 versus 22.5), indicating that, given LDL-P, the HDL subclasses did not contribute additional predictive value over HDL-P for major occlusive coronary event.
Ischemic stroke showed no significant association with any of the HDL-related measures. Other cardiac events were strongly associated with HDL-P and with mean HDL particle size, given HDL-P (HR, 0.84 [95% CI, 0.79 -0.90] and 1.13 [95% CI, 1.05-1.21], respectively; Figure 2 ). Table III in the online-only Data Supplement shows that these associations derived from inverse associations of risk with small HDL-P and medium HDL-P (HR, 0.82 [95% CI, 0.76 -0.89] and 0.81 [95% CI, 0.74 -0.89], respectively, in analyses of the subclasses jointly). This pattern of association was most apparent in the absence of adjustment for N-BNP, suggesting that preexisting cardiac insufficiency (as indicated by higher N-BNP) was also associated with this HDL pattern. Lack of adjustment for N-BNP also affected the relative strengths of the associations of the HDL-related measures with major occlusive coronary event, causing the HDL-P association to appear stronger (Figure 3) . The associations of HDL-related measures with any major coronary event (ie, including 449 heart failure or sudden deaths believed to have an underlying coronary cause) also weakly reflected the pattern seen for other cardiac event.
Influence of Prior Disease
The adjustments for prior disease (included in all analyses) had little net effect on the LDL-related associations. In contrast, HDL-C and HDL-P associations were considerably attenuated by the adjustment for prior disease-related factors. For example, 2 values for the associations with major occlusive coronary event were reduced by 50% to 60% after further adjustment beyond age, sex, allocated treatment arm, smoking, and blood pressure ( Table IV in HDL-P than for HDL-C, largely through the additional association of HDL-P with N-BNP (Table IV in the onlineonly Data Supplement and Table 2 ).
Findings in this investigation did not differ by sex (Figures III and IV in the online-only Data Supplement), and almost all participants (97%) were white.
Discussion
In this large study, there was no clear evidence of a difference in the strengths of the associations of any of the particle or cholesterol-based LDL-related measures with major occlusive coronary events or revascularization (1580 such events in the statin arm, 2010 in the placebo arm). The lack of Additional predictive value of subclasses over HDL-P, 2 2 § 9.3 0.01 1.6 0.45 LDL-P indicates particle concentration of low-density lipoprotein; HR, hazard ratio; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; ApoA 1 , apolipoprotein A 1 ; and HDL-P, particle concentration of HDL.
*Analyses are adjusted for age, sex, simvastatin and vitamin allocation, smoking, prior disease, systolic blood pressure, estimated glomerular filtration rate, medication, and N-terminal pro-B-type natriuretic peptide.
†All standard deviations are as in Figure 2 . ‡HRs for all HDL subclasses are per 5.18 mol/L (1 SD of HDL-P). §Calculated from the difference between the 2 3 for the subclasses jointly and the 2 1 for HDL-P alone.
Figure 3.
Comparison of the predictive strengths of high-density lipoprotein (HDL)-related measures, given particle concentration of low-density lipoprotein, for vascular events with and without adjustment for N-terminal pro-B-type natriuretic peptide (N-BNP; all participants). Major coronary event is the combination of nonfatal myocardial infarction or coronary heart disease death, death caused by heart failure (with underlying cause CHD), and sudden death. HDL-C indicates HDL cholesterol; Apo A 1 , apolipoprotein A 1 ; and HDL-P, particle concentration of HDL.
additional predictive value from LDL subclasses or LDL mean size among people with prior vascular disease in this study is consistent with the results from the most informative of the previous studies, which were in populations without prior cardiovascular disease (European Prospective Investigation into Cancer [EPIC]-Norfolk with 1003 coronary artery disease cases, 18 Women's Health Study [WHS] with 1015 cardiovascular cases 17 ). Other studies have reported mixed results, 10 but the variety of approaches to measurement and statistical analysis makes a consensus summary of them difficult. Furthermore, improvements in assay methods and standardization 23, 27 may have altered the relative predictive values of different measures. The strengths of the associations of the LDL-P subclasses with occlusive events in the present study broadly reflected their correlations with LDL-P. Small LDL-P was the subclass most strongly correlated with LDL-P, but its association with major occlusive coronary event risk was weaker than that of LDL-P. The lack of added predictive value from the subclasses cannot be attributed to differences in reproducibility because the reproducibility of the LDL subclasses (in samples collected a few years apart) was similar to that of the 4 total LDL-related measures. These 4 measures were strongly correlated with each other (Ϸ0.8 or higher) in the present study, whereas the correlations between cholesterol and particle measures in the EPIC-Norfolk and WHS studies were somewhat weaker (eg, Ϸ0.63 between LDL-P and LDL-C).
The ERFC meta-analysis of Ͼ4000 CHD events in people without prior vascular disease also found that non-HDL-C and apoB (and LDL-C, which was available for Ϸ2000 cases) had similar strengths of association with CHD. 2 This finding, however, differs from those of earlier large retrospective case-control studies in acute MI, which reported that apolipoproteins were superior predictors of MI than cholesterol fractions, 28, 29 but this difference may be explained by distortions of HDL-C levels in the hours after an acute MI when apolipoproteins may be more robust measures. The HR for major occlusive coronary event per unit of non-HDL-C (1.22 per 0.34 mg/dL in the statin arm) in the present study was low compared with that found in the ERFC meta-analysis (1.56 per 0.29 mg/dL after correction for within-person variation). In the present study, within-person variation, together with some variation in statin use (even in the statin arm), resulted in correlations of only Ϸ0.55 between baseline and midstudy non-HDL-C values (data not shown), which would attenuate associations with risk. The weaker HRs observed in this high-risk population would also be consistent with the weaker HRs seen at older ages and higher systolic blood pressure in previous large meta-analyses. 1, 2 The weaker and indefinite associations with ischemic stroke in the present study are also consistent with the relative strengths of the associations of non-HDL-C with coronary events and with ischemic stroke in the ERFC (in which, based on 1800 strokes, the log hazard ratios were only a quarter as great for ischemic stroke as for CHD). NMR-measured lipoprotein subclass measurements did not provide any insight into the discordance between the weak observational findings and the effect of LDL-lowering therapy on ischemic stroke.
HDL-C and HDL size were more strongly correlated than apoA 1 or HDL-P were with the total LDL-related measures. Thus, adjustment for LDL-P attenuated the risk association with HDL-C more than it attenuated the risk associations with apoA 1 and HDL-P. The weak levels of association of all HDL measures with CHD, however, limited the power to discriminate between these measures. The correlation of baseline HDL-C with repeat measurements obtained during follow-up was strong (0.82), so allowance for within-person variation 30 would only increase the strength of association modestly (eg, from 0.90 to 0.88). The modest HRs for the HDL-related measures found in this high-risk population (compared with ERFC) may indicate a tendency to weaker associations in less healthy individuals, as suggested by the marked trends with age and systolic blood pressure in the ERFC analyses. 2 Such attenuation may be a manifestation of HDL becoming dysfunctional in individuals with existing cardiovascular disease. 15, [31] [32] [33] [34] Adjustment for prior disease, including for N-BNP as a marker of heart failure, considerably attenuated associations with HDL-related measures, highlighting the potential for confounding by preexisting disease and for conflicting observations from studies with differing degrees of adjustment.
A strong inverse association was seen between small HDL-P and both N-BNP and other cardiac event risk ( Table  2 and Table III in the online-only Data Supplement). Because cardiac events in this study occurred predominantly in participants who had preexisting cardiac disease at entry, it is not possible to determine whether the association represents a causal or reverse-causal effect (ie, whether higher small HDL-P protects against the risk of a cardiac event 7 or whether lower small HDL-P is a consequence of the preexisting disease). Small and large mean HDL sizes were associated with different forms of prior disease: Small mean HDL size was associated with high triglycerides and LDL-P and with other features of the metabolic syndrome (Table 2) , as previously noted in the EPIC-Norfolk study, 35 and large mean HDL size was associated with high N-BNP and other cardiac event risk.
The present large study was prospective in design and, in contrast to previous studies, was able to look separately at associations of lipoprotein subclasses with coronary events, other cardiac events, ischemic strokes, and revascularizations. Another strength of this study was that it included detailed adjustment for prior vascular disease and other established risk factors. It extends previous results, showing similar strengths of risk association with different LDL and HDL measures in a population at higher risk of occlusive coronary event (average, 2%/y). Published studies have suggested that the magnitude of some associations of lipid levels with risk may attenuate with increasing levels of risk factors (such as age and systolic blood pressure); thus, it is a limitation of this study that the observed associations may be representative of only this type of high-risk population.
Conclusions
In a wide range of individuals at varying levels of cardiovascular risk, lipoprotein particles, apolipoproteins, and cholesterol fractions of LDL are of similar predictive value for major occlusive coronary events, and LDL subclasses provide little additional information. Lipoprotein particle number measurements could be considered an alternative to LDL and HDL cholesterol measurements for risk prediction if they became available at a similar cost. Measurement of a particlebased measure for LDL such as apoB or LDL-P also makes more biological sense because these measurements are of particles attached to the arterial wall. 36 Associations of HDL-related measures with risk are considerably influenced by prior disease; in particular, interpretation of the relationship between HDL particle measures, prior disease, and risk of other cardiac events requires further study.
